Ocrelizumab (Ocrevus): MS Clinical Trials

34 active trials · 17 recruiting

34 active multiple sclerosis clinical trials involve Ocrelizumab (Ocrevus), 17 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.

Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.

Active Ocrelizumab (Ocrevus) MS trials

Recruiting

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab

842 participantsDetails ›

RecruitingPhase 2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation

8 states182 participantsDetails ›

RecruitingPhase 2

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

RO7268489 · Ocrelizumab

360 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Remibrutinib oral treatment · Ocrelizumab

18 states360 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

60 participantsDetails ›

Recruiting

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Sponsor: Northwestern University

GLP-1 · Ocrelizumab (US)

1 state100 participantsDetails ›

RecruitingPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Sponsor: Sandoz

CYB704 · Ocrevus-EU

1 state175 participantsDetails ›

RecruitingPhase 3

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Sponsor: Hoffmann-La Roche

Ocrelizumab

500 participantsDetails ›

RecruitingPhase 3

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Sponsor: Rennes University Hospital

Perfusion of treatment Rituximab · Perfusion of treatment Ocrelizumab

386 participantsDetails ›

RecruitingPhase 3

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Ocrelizumab Injection [Ocrevus] · Ocrelizumab Injection [Ocrevus]

244 participantsDetails ›

RecruitingPhase 3

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Sponsor: Biocad

BCD-281 · Ocrelizumab

292 participantsDetails ›

Recruiting

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Sponsor: Biogen

Diroximel Fumarate · Alemtuzumab

1 state1178 participantsDetails ›

RecruitingPhase 3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Sponsor: Celltrion

CT-P53 · US-Ocrevus

512 participantsDetails ›

Recruiting

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Sponsor: Wayne State University

Observation of Ocrelizumab as Treatme…

1 state80 participantsDetails ›

RecruitingPhase 4

Home Based Infusions for Ocrelizumab

Sponsor: University of Colorado, Denver

Ocrelizumab at home

1 state110 participantsDetails ›

By invitation onlyPhase 4

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Sponsor: University of California, San Francisco

Ocrelizumab

1 state5 participantsDetails ›

Closed to new patientsPhase 4

Effects of Ocrevus in Relapsing Multiple Sclerosis

Sponsor: Georgia State University

Ocrelizumab · Platform

1 state60 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab · Placebo

5 states1013 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 4

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Sponsor: University of California, San Francisco

Ocrelizumab

1 state30 participantsDetails ›

Closed to new patientsPhase 2

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

5 states23 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patientsPhase 3

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Sponsor: Rigshospitalet, Denmark

Rituximab · Ocrelizumab

600 participantsDetails ›

Closed to new patientsPhase 3

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Sponsor: Haukeland University Hospital

Rituximab · Ocrelizumab

214 participantsDetails ›

Closed to new patientsPhase 3

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Sponsor: Haukeland University Hospital

Cyclophosphamide and ATG · Alemtuzumab

100 participantsDetails ›

Closed to new patients

Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS

Sponsor: Dr Recai Turkoglu

Ocrelizumab

30 participantsDetails ›

Closed to new patientsPhase 3

LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

Sponsor: Centre Hospitalier Universitaire de Nice

Ocrelizumab

72 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active Ocrelizumab (Ocrevus) MS trials

MS trials by therapy